| HM | CT | |
| Subjects n | 25 | 25 |
| Age yrs | 11.0 (9.3–12.4) | 11.2 (8.4–13) |
| Males | 18 (72) | 19 (76) |
| Duration of asthma yrs | 6.0 (3.3–8.3) | 4.3 (3.2–5.2) |
| ≥2 hospitalisations for asthma during the past year | 7 (28) | 5 (20) |
| Ever ICU admission | 4 (16) | 2 (8) |
| Pre-β2-agonist FEV1 % pred | 87.4 (79.9–103.0) | 83.3 (72.4–96.2) |
| Pre-β2-agonist FEF25–75% % pred | 53.6 (41.1–73.7) | 51.3 (37.5–68.9) |
| Post-β2-agonist FEV1 % pred | 110 (101–112) | 103 (95–108) |
| Post-β2-agonist FEF25–75% % pred | 84 (69–95) | 81 (66–100) |
| ICS dose μg equivalent BUD·day−1 | 1000 (800–1200) | 1200 (800–2000) |
| PAQLQ overall score | 4.2 (3.7–4.8) | 4.2 (3.4–5.3) |
| PAQLQ domains | ||
| Symptoms | 3.8 (3.4–4.7) | 4.0 (3.1–5.0) |
| Activities | 3.6 (3.2–4.2) | 4.0 (2.6–4.8) |
| Emotions | 4.9 (4.2–6.1) | 5.1 (3.9–6.4) |
| Other allergic features | ||
| Rhinitis | 10 (40) | 11 (44) |
| Eczema | 14 (58) | 7 (28) |
| Food allergy | 5 (21) | 3 (12.5) |
Data are presented as median (interquartile range) or n (%), unless otherwise stated. HM: home monitoring, CT: conventional treatment; ICU: intensive care unit; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FEF25–75%: forced expiratory flow at 25–75% of forced vital capacity; ICS: inhaled corticosteroids; BUD: budesonide; PAQLQ: Paediatric Asthma Quality of Life Questionnaire.